Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
about
Colony-stimulating factors for chemotherapy-induced febrile neutropeniaPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French SA single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialImpact of acute hematological toxicity on treatment interruptions during cranio-spinal irradiation in medulloblastoma: a tertiary care institute experience.Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialInduction and regulation of endogenous granulocyte colony-stimulating factor formation.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.The war on cancer: a report from the front linesColony stimulating factors for chemotherapy induced febrile neutropenia.Guidelines for the treatment of elderly cancer patients.Evidence-based use of colony-stimulating factors in elderly cancer patients.Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.The colony-stimulating factors: use to prevent and treat neutropenia and its complications.Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma.Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Supportive therapy in medical therapy of head and neck tumors.Immunomodulatory therapy in yeast infections.Senior adult oncology.Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohortG-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis.Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
P2860
Q24193040-E10CD32C-293C-4791-B174-6371A7279FF9Q24198118-11A58950-1B1B-426C-9035-4308CF512BFDQ24240753-93FCB06E-21F0-4033-8B96-87FD3C4DD180Q24241680-BB10547C-1607-4F7E-B21C-61DF2D83F3D0Q27320711-6DCAEDE3-BA50-43A1-AC7F-E2073A53E6CAQ33350688-F8DCB343-0C3F-4ED7-BC30-EB9CE321D29BQ33442381-BAF52A14-931B-4B7A-B92E-E305EDC36B2BQ33539387-94427E5E-139A-477E-AB0A-95A6A59F65E0Q34013208-624AA7C6-0724-4885-9821-BB268724CCF7Q35009279-B801BE7F-0453-48F2-B331-9D1B5FA839DEQ35044368-B9C6E758-5436-453D-BEDC-00E82A5F535BQ35103643-9AEAC231-3D28-4C5C-B83B-3CFD8553257FQ35199419-3EB3CE2B-218F-4B0F-BA4F-D66213C2A2F4Q35599058-4D5497DB-084A-44A6-899A-F93E51F7BE1AQ35599074-7ED27D0F-2DF5-4729-A4CD-EFACA3B2DB88Q35642536-3B997A73-E7D5-4F6C-98D3-7A72CB9427BCQ35967278-92D0C6C7-578D-4B50-9986-578BFFA03671Q35998006-5567E17E-2950-4CFA-9F0C-5B59C1884EFDQ36327074-091DF77D-2B35-4171-BD66-17EC4D998A88Q36443085-99F9D852-6FA7-4D7D-B1CE-480FE537D796Q36485208-8BB42994-4D2A-4051-9735-791BD3E91E89Q36529853-C4E143D9-AADA-4FF8-A14D-BCF3D47B98AEQ36723814-34C258BE-AF5F-4575-A4E8-C90CF44C0FEEQ36851424-5CA2EDA9-0176-4A8E-9B35-64490FA705C5Q36949179-7FB0B839-94A7-45DC-B1F3-68E120876F12Q37149710-631C0152-92B0-42A1-9859-499EC168170BQ37241723-E44FA7CE-273A-468F-B4C7-79982574B886Q37788578-8FF27C88-D16A-4B61-9C7D-6632DDC8C6F1Q37931905-A1DE70A9-4829-40C6-ACA9-38508C820BD3Q37996443-9F67A8D9-0222-42D3-B359-81C1AAA4E88BQ38195261-5573D871-7FD9-43E4-A7B0-37CF3A075209Q38269589-F6474B52-7E64-49C9-95A1-93646C1BB9D2Q39524475-2350AE76-DBAE-4A5A-8FB2-E9F9CF87702AQ40240657-DAF48FC4-9505-4311-AEC1-85EB51144C25Q40245653-86408D8C-10C1-46DE-A6B4-65A1ECF12AB5Q40265492-4D7A325A-BC16-4993-BEE3-3DCE80FC9564Q40363722-001816A7-BE46-43FA-B838-A5DEC8376E18Q40472794-DDEE1DFB-9B9B-411B-A601-5F26D02C9EF0Q40540422-4733D625-9033-423F-BB19-82C814A57508Q40810746-39CB2BFB-501E-4EF2-9C21-31498CF43255
P2860
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@ast
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@en
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@nl
type
label
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@ast
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@en
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@nl
prefLabel
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@ast
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@en
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@nl
P921
P1476
Prophylactic granulocyte colon ...... chemotherapy: a meta-analysis.
@en
P2093
Gary H Lyman
Nicole M Kuderer
P304
P356
10.1016/S0002-9343(02)01036-7
P407
P577
2002-04-01T00:00:00Z